Parodi O, Marzullo P, Sambuceti G, Neglia D, Gimelli A, Giorgetti A
CNR Institute of Clinical Physiology, Pisa, Italy.
Int J Card Imaging. 1993;9 Suppl 1:19-29. doi: 10.1007/BF01143143.
The failure of non-imaging techniques in identifying viable segments has favoured the clinical application of nuclear imaging. The main pathways that support radionuclide imaging are cell membrane integrity, persistence of intermediary metabolism and demonstration of a residual coronary reserve. Thallium-201 reinjection or rest protocols allow the identification of viable myocardium in most of patients with wall motion abnormalities and appear to be the most diffuse, low-cost and available method to detect viable myocardium. More complex approaches use positron emission tomography and matched flow/metabolic information. Flow/metabolic 'mismatch' usually identifies most of hypoperfused regions that show post-operative improvement of regional wall motion. The last promising approach is represented by the demonstration of a maintained regional coronary reserve in dyssynergic areas. Technetium-99m-microspheres (or Teboroxime in the future) can be successfully used for this purpose. The clinical application of radionuclides appears to be one of the principal imaging tools able to identify residual viability.
非成像技术在识别存活心肌节段方面的失败促使了核成像技术在临床上的应用。支持放射性核素成像的主要途径包括细胞膜完整性、中间代谢的持续性以及残余冠状动脉储备的显示。铊-201再注射或静息方案能够在大多数存在室壁运动异常的患者中识别存活心肌,并且似乎是检测存活心肌最普及、成本最低且最容易获得的方法。更复杂的方法则采用正电子发射断层扫描以及匹配的血流/代谢信息。血流/代谢“不匹配”通常能够识别出大多数灌注不足的区域,这些区域在术后室壁运动可得到改善。最后一种有前景的方法是通过证明运动失调区域存在局部冠状动脉储备得以实现。锝-99m微球(或未来的替硼肟)能够成功用于此目的。放射性核素的临床应用似乎是能够识别残余存活心肌的主要成像工具之一。